"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price, " said Leena Menghaney of medical humanitarian aid organization Medecins Sans Frontieres.

NPR: India Rejects Bayer Plea Against Cheap Cancer Drug